Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RG 6146

Drug Profile

RG 6146

Alternative Names: RG6146; RO 6870810; TEN 010

Latest Information Update: 02 Jun 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tensha Therapeutics
  • Developer Roche
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Diffuse large B cell lymphoma; Multiple myeloma; Myelodysplastic syndromes; Ovarian cancer; Solid tumours; Triple negative breast cancer

Most Recent Events

  • 10 Apr 2021 Efficacy and adverse events data from a phase I trial in Ovarian cancer and Breast cancer presented at the 112th Annual Meeting of the American Association for Cancer Research (AACR-2021)
  • 05 Dec 2020 Efficacy, pharmacokinetics and adverse events data from a phase I trial in Multile myeloma presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology (ASH-2020)
  • 16 Oct 2019 Discontinued - Phase-I for Multiple myeloma (Combination therapy, In the elderly, Late-stage disease, Second-line therapy or greater, In adults) in United Kingdom, after October 2019 (SC) (NCT03068351)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top